| Blood glucose | - Post prandial – Target <140 mg/dL (7.8 mmol/L) at 1 to 2 hours.
- Fasting blood glucose – Target 70 to 90 mg/dL (3.9 to 5 mmol/L), when on basal insulin.
|
| A1C | Check every 3 months. Aim for low-normal values (eg, <5.5%). A1C values should decrease after initiating insulin. |
| Continuous glucose monitoring | - For screening – May be helpful if a patient has dysglycemia and indications for insulin treatment are unclear.
- For treatment – Suggested if a patient is on insulin but has poor growth.
|
| Complications screening[1] | Blood pressure measurement at all routine visits. Annual screening for microvascular complications, beginning 5 years after the diagnosis of CFRD: - Dilated eye examination for retinopathy
- Urine albumin:creatinine ratio (spot specimen)
- Foot examination with testing for vibration (tuning fork) and pressure (10 g monofilament)
- Lipid profile for selected patients with risk factors for hyperlipidemia (post transplantation, obesity, or family history of early coronary artery disease)
|
| Pulmonary function testing | Perform every 3 months to assess lung function. Optimal therapy for CFRD tends to improve pulmonary function. |
